Vascular Graft Solutions News
11 articles
Vascular Graft Solutions Acquires the Intellectual Property Developed by Kipsbay Medical Inc.
Vascular Graft Solutions (VGS) has announced the acquisition of several patent families from NEOGRAFT Technologies Inc., which include patents previously owned by Kipsbay Medical Inc. The acquisition will broaden VGSs existing portfolio and enhance the protection of its suite of technologies for coronary bypass, peripheral vascular reconstruction, and repair of high flow AV fistula. The new patents and know-how will enable VGS to explore new approaches to create blood vessels that are resistant to the development of atherosclerosis. VGS is a leading developer of innovative technologies for surgical revascularization and vascular reconstruction procedures. The company is headquartered in Tel-Aviv, Israel.
Acquisition
Vascular Graft Solutions Announces CE Mark Approval for FRAME FR External Support for AV Fistula Repair
Vascular Graft Solutions Ltd. has received CE Mark Approval for the FRAME FR, a novel solution for repair and stabilization of high flow and aneurysmal arteriovenous fistulas in hemodialysis patients. The company aims to address one of the leading causes of morbidity and mortality in these patients - the toxic effect of the vascular access on the heart. The solution reduces and maintains the flow within the normal range and has the potential to minimize venous remodeling and mitigate intimal hyperplasia. Clinical experience with FRAME FR has shown safety and effectiveness in providing stable flow reduction. Long-term clinical follow-up will be presented at the VEITH meeting in NY in November 2019.
Customers
Long-term performance of an external stent for saphenous vein grafts: the VEST IV trial - Journal of Cardiothoracic Surgery
A study has found that the VEST external stent, developed by Vascular Graft Solutions, significantly reduces intimal hyperplasia and the development of lumen irregularities 4.5 years after coronary artery bypass surgery. The study found that the benefits of external stents on improving Fitzgibbon perfect patency and reducing intimal hyperplasia that was demonstrated at 1 year are maintained at 4.5 years. The study also found that the distance of the VEST stent from the SVG lumen was an important determinant of the degree of intimal hyperplasia.
Customers
Vascular Graft Solutions Honored by Goldman Sachs for Entrepreneurship as Eyal Orion, Its Founder and CEO, is Among 100 Most Intriguing Entrepreneurs at 2018 Builders + Innovators Summit
Goldman Sachs has recognized Dr. Eyal Orion, founder and CEO of Vascular Graft Solutions, as one of the 100 Most Intriguing Entrepreneurs of 2018 at its Builders + Innovators Summit. Dr. Orion is actively involved in several medical device companies and is focused on developing innovative technologies in the field of cardiovascular surgery. Vascular Graft Solutions aims to provide solutions for the prevention of vein graft disease following bypass procedures. The companys vision is to improve bypass surgery by addressing the unmet needs of the procedure. Dr. Orion expressed gratitude for the recognition and emphasized the importance of innovation and collaboration in building sustainable businesses. The Builders + Innovators Summit aims to support emerging leaders in their quests to innovate and grow their ideas.
Partners
Vascular Graft Solutions Reports the First Clinical Use of Its FRAME External Support Technology in Aneurysm Repair of High Flow Arteriovenous Fistulas
Vascular Graft Solutions reports the first clinical use of its FRAME external support technology for aneurysm repair in high flow arteriovenous (AV) fistulas. The first 5 cases were performed by Dr. Vladimir Matoussevitch from Cologne University Hospital in Germany. The technology has the potential to prevent serious clinical complications and reduce post-procedure flow in high flow fistulas. Vascular Graft Solutions is looking forward to expanding their experience with FRAME in collaboration with vascular surgeons.
Customers
John Radcliffe Oxford University Hospital is the First Medical Center in the UK to Use VEST Technology in Patients Undergoing Coronary Bypass Surgery
Vascular Graft Solutions announces that John Radcliffe hospital in Oxford is the first center in the UK to use its VEST technology for coronary bypass surgery. The technology has the potential to improve the quality and outcomes of surgery. The company expresses gratitude to the team at John Radcliffe hospital for their contribution and looks forward to future projects with them. Vascular Graft Solutions is a privately held company based in Tel Aviv, Israel, that develops novel solutions for cardiac and vascular surgeries.
Partners
VGS Initiates U.S. Pivotal Trial to Evaluate the Use of Its VEST Technology for Bypass Surgery
Vascular Graft Solutions Ltd (VGS) has enrolled the first 20 patients into the VEST US pivotal trial, which will evaluate the safety and effectiveness of the VEST, an external support device for the treatment of saphenous vein graft disease after coronary artery bypass grafting (CABG). The trial is being conducted under an FDA Investigational Device Exemption (IDE) and the auspices of the NIH-sponsored Cardiothoracic Surgical Trials Network (CTSN). The VEST trial represents a collaboration between researchers, FDA, and NIH to conduct high-impact clinical research. The first two VEST implantations were successful, and the device is being integrated into the routine CABG procedure. The trial aims to improve the function of vein grafts and prevent early changes in veins that lead to vein failure during long exposure to arterial pressure.
Customers
Vascular Graft Solutions: External Stenting of Vein Grafts is Associated With High Early Patency Rates
Vascular Graft Solutions announced the interim results from the VEST III study, which evaluates the effectiveness of their VEST technology in treating saphenous vein graft disease. The study showed promising results with 100% early patency rates in the stented grafts. VEST is the only technology that has demonstrated clinical effectiveness in mitigating vein graft disease five years after surgery. The company is focused on developing and marketing medical technologies in cardiac and vascular surgery.
Customers
prospective study of external stenting of saphenous vein grafts to the right coronary artery: the VEST II study
OCT imaging of aorto-coronary vein graft pathology modified by external stenting: 1-year post-surgery
Expandable external support device to improve Saphenous Vein Graft Patency after CABG - Journal of Cardiothoracic Surgery
A study has found that an expandable external support system developed by Vascular Graft Solutions could improve the patency rates of saphenous vein grafts (SVGs) after surgical myocardial revascularization. The research, conducted on sheep, found that the device was effective in reducing SVGs non-uniform dilatation and neointimal formation. The device is designed to prevent kinking, non-uniform dilation, and wall thickening, which are known to cause early and late graft failure. The first trial with the expandable support system is currently being conducted in the UK.
Expand
